Clinical Trials

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

500 enrolled

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

BreastGastrointestinalSarcoma

Breast Neoplasms

NCT05735080 2025-09-19

INX-315-01

Phase 1/2 Recruiting

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT04752332 2025-07-15

eMonarcHER

Phase 3 Terminated

111 enrolled 9 charts

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

5,500 enrolled

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03155997 2025-04-20

monarchE

5,637 enrolled 12 charts 2 FDA

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

29 enrolled

Breast Neoplasms

NCT03763604 2024-12-16

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing

Breast Neoplasms

NCT02675231 2024-11-26

monarcHER

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT02791334 2024-09-27

PACT

BreastDermatologicGastrointestinal

164 enrolled

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT03703466 2024-04-02

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

72 enrolled 19 charts

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast Neoplasms

NCT04791384 2023-07-27

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Unknown

44 enrolled

Breast Neoplasms

NCT04514159 2023-02-01

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

14 enrolled

Breast Neoplasms

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

BreastLymphoidOther solid neoplasmThoracic

156 enrolled

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Completed

4,320 enrolled

Breast Neoplasms

NCT05141240 2021-12-16

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Completed

4,650 enrolled

Breast Neoplasms

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Phase 4 Terminated

4 enrolled 9 charts

Breast Neoplasms

NCT02441946 2020-06-17

neoMONARCH

224 enrolled 20 charts

Breast Neoplasms

NCT02102490 2020-01-21

MONARCH 1

132 enrolled 17 charts 1 FDA

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Phase 4 Withdrawn

Breast Neoplasms

NCT02792725 2017-10-31

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing